Expanded-access use of elamipretide in a newborn with Barth syndrome: a case report
European Heart Journal - Case Reports

Abstract
Barth syndrome (BTHS) is a rare genetic disease, with no approved curative therapies, characterized by abnormally developed cardiolipin, resulting in mitochondrial dysfunction. Cardiomyopathy, a common clinical manifestation of BTHS, often appears in infancy. Elamipretide, an investigational drug that binds to cardiolipin on the inner mitochondrial membrane, leads to improved membrane stability, enhanced adenosine triphosphate production, and reduced reactive oxygen species. This patient case aims to further support elamipretide’s role in treating BTHS infants.
We present an infant diagnosed
Our case suggests that elamipretide may have contributed to the improvement of LV function in this BTHS infant, supporting elamipretide’s early use in BTHS. Our findings align with the previous studies in which elamipretide treatment demonstrated normalization of mitochondrial function and improvement in LV function.
Contributors

Laura Ortmann
Author

Danita Velasco
Author

Jason Cole
Author

Luca Monzo
Author

Vincenzo Nuzzi
Author

Giulia Bruno
Author

Faris Kadíc
Author
You may be interested in



